ACLY, ATP citrate lyase, 47

N. diseases: 109; N. variants: 6
Disease: Fatty Liver ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.030 AlteredExpression disease BEFREE Additionally, hepatic SIRT2 overexpression decreased ACLY-3K acetylation and its protein level and alleviated hepatic steatosis in HF/HS diet-fed mice. 31197036 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.030 Biomarker disease BEFREE ACLY is also a target against dyslipidaemia and hepatic steatosis, with a compound currently in phase 3 clinical trials<sup>4,5</sup>. 30944472 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.030 Biomarker disease BEFREE Metabolic pathways are built to elucidate the mechanisms by which VIRG host's higher energy requirements were met: including gene up-regulations for intestinal gluconeogenesis (PEPCK) and liver glycolysis (ENO2), and intriguingly liver fatty acid synthesis through ATP citrate synthase (CS) down-regulation and ATP citrate lyase (ACLY) and malic enzyme (ME) up-regulations. 22272335 2012